American Transplant Congress, Seattle | 18–22 May 2013

The American Transplant Congress was held between May 18-22 in Seattle this year. The American Transplant Congress is the premier venue for scientific exchange between the various disciplines uniquely involved in solid organ transplantation.

Plexision’s exhibit profiled its rejection-risk test, Pleximmune, and upcoming assays aimed at measuring anti-viral immunity at this conference.

Visitors expressed a strong interest in determining whether renal allograft dysfunction could be attributed to loss of anti-viral immunity in patients demonstrating BK viruria. Plexision's upcoming tests should address this need within the next three months.

Another need among adult liver transplant recipients is distinguishing exacerbations of hepatitis C from acute cellular rejection. This particular problem is not always resolved by liver transplant biopsies. Clinicians acknowledged that measuring an exuberant donor-specific alloresponse, which is known to cause rejection, could be a valuable adjunct in formulating immunosuppression strategies for such patients.

Plexision develops cellular biomarkers for personalized diagnostics and drug development in organ transplantation and immunological disorders.